<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496455</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-S</org_study_id>
    <nct_id>NCT02496455</nct_id>
  </id_info>
  <brief_title>The Impact of the SCN9A Gene Polymorphism on Postoperative Pain</brief_title>
  <official_title>The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokat Gaziosmanpasa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokat Gaziosmanpasa University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to determine the association between postoperative pain after
      cesarean section and several single nucleotide polymorphisms in SCN9A sodium channels gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCN9A gene encodes an alpha subunit of the voltage-gated sodium channel (Nav1.7) and
      polymorphisms of this gene are associated with severe pain disorders. The impact of the
      polymorphisms in SCN9A on postoperative pain and opioid consumption after cesarean section is
      unclear.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>up to postoperative 24 hours</time_frame>
    <description>The pain will be evaluated with the visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>Up to postoperative 24 hours</time_frame>
    <description>The total amount of the tramadol administered to the patient will be recorded</description>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Pregnancy</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cesarean section</intervention_name>
    <description>Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opioid Tramadol</intervention_name>
    <description>Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period</description>
    <other_name>Tramadol (contramal)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two ml blood will be collected from the peripheral venous before the operation and all blood
      samples will be stored at -80℃. Genomic DNA will be extracted from the blood samples and
      polymorphism in SCN9A gene will be identified by PCR
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The women in 36 to 40 weeks of pregnancy undergoing cesarean section will be included
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The women aged 18 to 45,

          -  in 36 to 40 weeks of pregnancy

          -  undergoing cesarean section

        Exclusion Criteria:

          -  History of chronic pain or pain disorders

          -  Psychiatric diseases

          -  Diabetes mellitus

          -  Severe cardiovascular, kidney or liver diseases

          -  Alcohol or drug abuse

          -  Heavy smoker

          -  Unable to use the Patient controlled analgesia (PCA) pump
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tugba Karaman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gaziosmanpasa University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gaziosmanpasa University Medical School Hospital</name>
      <address>
        <city>Tokat</city>
        <zip>60100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokat Gaziosmanpasa University</investigator_affiliation>
    <investigator_full_name>Tuğba Karaman</investigator_full_name>
    <investigator_title>Assistant Professor, M.D.</investigator_title>
  </responsible_party>
  <keyword>NAV1.7 Voltage-Gated Sodium Channel</keyword>
  <keyword>pain, postoperative</keyword>
  <keyword>cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

